CA
NZ
UK
AU
IND
US
Janux Therapeutics (NASDAQ:JANX) shares were trading at $15.53 in pre-market activity on August 11, 2026, down 5.36% from the prior close of $16.41. The decline came despite the company posting second quarter revenue of $10.3 million, which beat the consensus estimate of $19.1 million, …
Lexeo Therapeutics (NASDAQ:LXEO) shares were trading at $4.81 in pre-market activity on August 11, 2026, up 3.89% from the prior close of $4.63. The move followed the company's announcement that the FDA granted Regenerative Medicine Advanced Therapy designation to LX2020, its investigational gene therapy …
Royal Philips (NYSE:PHG) shares were trading at $27.12 in pre-market activity on August 11, 2026, up 0.63% from the prior close of $26.94. The move followed the announcement that Philips and its top shareholder, Exor, agreed to update their long-term relationship agreement, providing Exor …
Today's session produced a sweeping rally across genomics, medical-device, data-security, and healthcare-services names. 10x Genomics (Nasdaq: TXG) surged nearly 13%, Butterfly Network (NYSE: BFLY), Rubrik (NYSE: RBRK), and LifeStance Health (NASDAQ: LFST) all gained more than 10%, and RadNet (NASDAQ: RDNT) added a further …
OmniAb (Nasdaq: OABI) shares closed up 38% at $3.08 after the company delivered a second-quarter revenue beat characterized by significantly improved sales and a reduced net loss.
Ardelyx (Nasdaq: ARDX) shares closed down 18% at $4 after management downwardly revised its full-year 2026 Ibsrela revenue projections to $350 million to $370 million, falling short of the previous $410 million to $430 million range.
Tenax Therapeutics (Nasdaq: TENX) reported that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed the primary 6-minute walk distance endpoint and key KCCQ symptom endpoint.
Silence Therapeutics (Nasdaq: SLN) announced that its Phase 2 SANRECO trial of divesiran in phlebotomy-dependent polycythemia vera achieved its primary endpoint, with 88% of patients reaching clinical response compared to 19% for placebo.
AVITA Medical (Nasdaq: RCEL) shares closed up 64% at $7.77 after the company reported second-quarter 2026 financial results and raised its full-year revenue guidance.
NRx Pharmaceuticals (Nasdaq: NRXP) shares closed up 16% at $3.58 after the company disclosed that the FDA finalized its preliminary ANDA assessment for preservative-free ketamine, finding no major issues with the drug itself.
Please wait processing your request...